trending Market Intelligence /marketintelligence/en/news-insights/trending/1kJTUpUuQ3gKJbFk_ZHUdg2 content esgSubNav
In This List

Principia Biopharma director dies

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Principia Biopharma director dies

Principia Biopharma Inc. said one of its directors, Lewis Shuster, has died.

The South San Francisco, Calif.-based company also said it fell out of compliance with the Nasdaq's listing rules as Shuster's death reduced the members of Principia's audit committee to two. The stock market requires listed companies' audit committees to have at least three members.

Principia plans to regain compliance by appointing a new independent director, the company said in a filing.

Principia develops oral therapies for immunology and oncology in the U.S.